https://scholars.lib.ntu.edu.tw/handle/123456789/635858
標題: | Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment | 作者: | Chang, Cheng-Yu CHUNG-YU CHEN Chang, Shih-Chieh Chen, Ching-Yi Lai, Yi-Chun Chang, Chun-Fu Wei, Yu-Feng |
關鍵字: | epidermal growth factor receptor-tyrosine kinase inhibitor; neutrophil-to-lymphocyte ratio; non-small-cell lung cancer; osimertinib; re-biopsy; second-line | 公開日期: | 2023 | 卷: | 13 | 來源出版物: | Frontiers in oncology | 摘要: | Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for advanced EGFR-mutant non-small-cell lung cancer (NSCLC) patients. However, factors associated with outcomes after progression on first-line therapy are seldom investigated. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/635858 | ISSN: | 2234-943X | DOI: | 10.3389/fonc.2023.1104098 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。